CymaBay Therapeutics Inc (NASDAQ:CBAY) Expected to Post Earnings of -$0.37 Per Share

Wall Street analysts expect CymaBay Therapeutics Inc (NASDAQ:CBAY) to report earnings per share (EPS) of ($0.37) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for CymaBay Therapeutics’ earnings. The lowest EPS estimate is ($0.40) and the highest is ($0.33). CymaBay Therapeutics reported earnings of ($0.34) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 8.8%. The business is scheduled to report its next earnings report on Tuesday, November 5th.

On average, analysts expect that CymaBay Therapeutics will report full-year earnings of ($1.47) per share for the current financial year, with EPS estimates ranging from ($1.55) to ($1.35). For the next fiscal year, analysts expect that the business will post earnings of ($1.68) per share, with EPS estimates ranging from ($1.85) to ($1.47). Zacks’ EPS averages are an average based on a survey of analysts that cover CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02.



CBAY has been the topic of a number of recent research reports. Stifel Nicolaus initiated coverage on shares of CymaBay Therapeutics in a research note on Monday, June 24th. They issued a “buy” rating and a $14.00 price objective on the stock. B. Riley set a $7.00 target price on shares of CymaBay Therapeutics and gave the company a “hold” rating in a report on Monday, June 17th. BidaskClub downgraded shares of CymaBay Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 30th. Evercore ISI reaffirmed a “buy” rating and issued a $15.00 target price on shares of CymaBay Therapeutics in a report on Wednesday, August 14th. Finally, Oppenheimer set a $12.00 target price on shares of CymaBay Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $14.09.

NASDAQ CBAY traded down $0.28 during trading on Friday, reaching $5.53. The company’s stock had a trading volume of 289,167 shares, compared to its average volume of 576,505. The company has a current ratio of 16.20, a quick ratio of 16.20 and a debt-to-equity ratio of 0.01. CymaBay Therapeutics has a twelve month low of $4.82 and a twelve month high of $14.00. The business’s fifty day moving average price is $6.21 and its 200-day moving average price is $10.03.

Hedge funds have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. boosted its holdings in CymaBay Therapeutics by 307.3% during the first quarter. Meeder Asset Management Inc. now owns 2,839 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 2,142 shares in the last quarter. Bank of Montreal Can boosted its holdings in CymaBay Therapeutics by 1,372.0% during the second quarter. Bank of Montreal Can now owns 6,771 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 6,311 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in CymaBay Therapeutics during the second quarter worth about $80,000. BNP Paribas Arbitrage SA purchased a new stake in CymaBay Therapeutics during the first quarter worth about $165,000. Finally, Aperio Group LLC purchased a new stake in CymaBay Therapeutics during the second quarter worth about $104,000. 96.07% of the stock is currently owned by hedge funds and other institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

See Also: What are different types of coverage ratios?

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.